Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS Registry
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
PURPOSE: Prostate cancer (PCA) germline testing (GT) informs precision therapy, cancer screening, and hereditary cancer risk for patients and families. To support patient-centered PCA GT, studying patient-reported outcomes (PROs) is essential. METHODS: PROGRESS was a national patient-driven registry (January 2021-April 2022) for English-speaking males older than 18 years with previous/current PCA GT and Internet access. Surveys collected demographics, PCA history, family cancer history, mode of genetics care delivery, satisfaction with genetic counseling, decisional conflict, cancer genetics knowledge, and attitudes toward GT. Multiple linear regression modeling was used to estimate and draw inferences (α = .05) on strength of relationships between participant characteristics and PROs. RESULTS: Analyses focused on 414 participants: White (88%), Black (3%), Asian (6%), and mixed/other (3%). Most participants were non-Hispanic (95.2%) and 46.9% had PCA. Genetic results were positive (pathogenic/likely pathogenic variants; mutations) in 27.9%. The three most common modes of genetics care were meeting with genetics professional (in-person or remotely; 30.9%), discussing with doctor (21.1%), and using website (20.8%). In covariate-adjusted models, satisfaction scores were highest with pretest counseling by phone (β = 1.31; 95% CI, 0.26 to 2.36) or discussion with doctor (β = 1.25; 95% CI, 0.38 to 2.12). Lower decisional conflict scores were reported for pretest counseling by phone (β = -3.76; 95% CI, -7.28 to -0.24). Males with mutations reported higher GT benefit scores (β = .30; 95% CI, 0.02 to 0.59) and importance of GT (β = .34; 95% CI, 0.08 to 0.61). Asian Americans reported lower GT satisfaction (β = -2.91; 95% CI, -4.34 to -1.48) and higher decisional conflict (β = 8.93; 95% CI, 4.36 to 13.51). CONCLUSION: PROGRESS Registry informs the first comprehensive report of PROs among males undergoing PCA GT, providing insights into opportunities to improve patient experience and leverage the benefit of GT.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS Registry
- Date Crossref
- 01/09/2025
- Éditeur
- American Society of Clinical Oncology (ASCO)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
New York University Department of Urology and Population Health pays non établi dans la noticeUniversité ou école supérieure
-
Thomas Jefferson University Department of Urology pays non établi dans la noticeUniversité ou école supérieure
-
Sidney Kimmel Cancer Center pays non établi dans la noticeÉtablissement de santé
-
Sidney Kimmel Comprehensive Cancer Center pays non établi dans la noticeStructure de recherche
-
Yale University pays non établi dans la noticeUniversité ou école supérieure
-
Oregon Health & Science University OHSU Knight Cancer Institute pays non établi dans la noticeUniversité ou école supérieure
-
Exact Sciences (United States) pays non établi dans la noticeEntreprise
-
Smilow Cancer Hospital pays non établi dans la noticeÉtablissement de santé
-
Fred Hutch Cancer Center pays non établi dans la noticeOrganisation à but non lucratif
-
National Cancer Institute Genitourinary Malignancies Branch pays non établi dans la noticeOrganisme public
-
Facing Our Risk of Cancer Empowered pays non établi dans la noticeOrganisation à but non lucratif
-
Summit School pays non établi dans la noticeUniversité ou école supérieure
Department of Urology and Population Health — New York University, Department of Urology — Thomas Jefferson University et Sidney Kimmel Cancer Center, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.